Drug Database
LA

lansoprazole + amoxicillin + clarithromycin (Lansap)

✓ Approved

Takeda · ATP4A · Small Molecule

What is lansoprazole + amoxicillin + clarithromycin?

lansoprazole + amoxicillin + clarithromycin is a small molecule developed by Takeda. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLansap
CompanyTakeda
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Takeda

Mechanism of Action

Molecular Targets

lansoprazole + amoxicillin + clarithromycin acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

lansoprazole + amoxicillin + clarithromycin is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersGastric ulcer✓ Approved
Infections and infestationsHelicobacter infection✓ Approved

Related Research Articles

PubMedRSC advances2026-11-11

Smart red berry-derived carbon nanofiber-polyethylene imine beads for controlled urea release, amoxicillin encapsulation and digital image colorimetry in soil by fast microwave method.

Tohamy Hebat-Allah S HS

A novel dual-mode optical sensor and controlled-delivery hydrogel system (CNF-PEI-AMX-Urea) was successfully engineered using biomass-derived carbon nanofibers (CNFs) decorated with active functional groups and co-entrapped with urea and amoxicillin (AMX). Morphological and structural evaluations confirmed an interconnected fibrous network with ultrafine widths ranging tightly between 2.40-4.76 nm and an amorphous-to-nanocrystalline sp2-hybridized graphitic framework. FTIR spectroscopy verified an intensely hydrophilic boundary layer rich in amine (3471 cm-1), hydroxyl (3372 cm-1), carbonyl (1669 cm-1), and graphitic carbon (1408 cm-1) functional groups, achieving a high operational degree of substitution of 0.52. The fabricated platform demonstrated striking dual-mode optical performance, functioning simultaneously as a daylight halochromic sensor exhibiting pronounced color difference (ΔE) values reaching 4.50 at pH 3 and 8.08 at pH 9 for blank beads, and 2.54 (pH 3) and 3.15 (pH 9) for the urea-loaded test system and as a pH-responsive fluorogenic probe under UV illumination with distinct emission shifts across acidic, neutral, and alkaline conditions. Furthermore, in vitro release studies conducted at a simulated soil pH of 6 demonstrated a slow, sustained, and diffusion-controlled delivery profile governed closely by the Higuchi model (R 2 = 0.9747 for urea, R 2 = 0.9811 for AMX), avoiding burst release and achieving 24-hour cumulative releases of 4.08% for urea and 15.58% for AMX. Overall, this multifunctional hybrid platform successfully unifies smart optical pH sensing with regulated agricultural delivery, presenting exceptional potential for intelligent real-time environmental monitoring and sustainable agricultural applications.

PMID 43011378
Read full article →
PubMedMedicine2026-11-11

An unusual case of chronic eyelid infection associated with Staphylococcus aureus and Morganella morganii: A case report.

Yang Ju-Wen JW, Chang Liang-Che LC

Morganella morganii is an uncommon opportunistic pathogen, and eyelid infections attributable to this organism are exceptionally rare. A 53-year-old male presented with persistent discharge and progressive structural changes of the left eyelid. Microbiological analysis of conjunctival discharge initially revealed oxacillin-susceptible Staphylococcus aureus and M morganii. Intraoperative cultures subsequently yielded methicillin-resistant S aureus (MRSA) and M morganii. Histopathological examination demonstrated acute and chronic inflammatory changes with fistulous tract formation. Initial empirical treatment included topical levofloxacin and tobramycin ophthalmic ointment, together with a brief course of oral amoxicillin/clavulanate. Based on subsequent culture and antimicrobial susceptibility findings, topical vancomycin was added to levofloxacin for 2 months, followed by intermittent topical antimicrobial therapy adjusted according to the clinical course. As conjunctival fistulae and chronic inflammation persisted despite extended medical treatment, surgical excision, limited debridement, and conjunctival wound closure were subsequently performed. Despite initial medical management, the patient developed multiple palpebral conjunctival openings and persistent fistulae over a 2-year period, with the discharge changing from purulent yellow secretions to thick, toothpaste-like material. Histopathological examination revealed acute and chronic inflammation with fistulous tract formation. Following surgical intervention, marked improvement was noted, including regression of the eyelid mass, closure of the fistulae, and resolution of discharge. At 1.5 years of postoperative follow-up, the eyelid remained stable without recurrence of fistulae or discharge. This case highlights a chronic polymicrobial eyelid and conjunctival infection involving S aureus and M morganii, with methicillin-resistant S aureus isolated at the time of surgery. The findings suggest that M morganii may contribute to sustaining chronic periocular infection in susceptible hosts. In this patient, persistent infection complicated by fistula formation ultimately required surgical management after prolonged antimicrobial therapy failed to achieve resolution.

PMID 43012777
Read full article →
PubMedBMC infectious diseases2026-11-11

Melioidosis on Phu Quoc Island, Vietnam: a retrospective case series from a remote tropical setting.

Le Duy-Cuong DC, Nguyen Dinh-Dung DD, Nguyen Thuy-Hang Thi TT, Vu Hanh H et al.

Melioidosis, caused by Burkholderia pseudomallei, is an important but frequently under-recognized cause of severe infection in tropical regions, including Vietnam. Although cases have been reported from several parts of the country, published clinical data from remote island settings remain scarce. To our knowledge, no clinical case series of melioidosis from Phu Quoc Island has been previously reported. This study describes the clinical presentations, underlying comorbidities, management, and outcomes of patients diagnosed with melioidosis at a tertiary hospital on Phu Quoc Island, Vietnam. We retrospectively reviewed all patients with culture-confirmed melioidosis admitted to Vinmec Phu Quoc General Hospital between July 2022 and February 2026. Archived isolates underwent molecular confirmation using a TTS1-targeted quantitative polymerase chain reaction (qPCR) assay, followed by recA gene sequencing. Nine patients were included. Clinical, laboratory, microbiological, radiological, treatment, and outcome data were extracted from medical records. Pneumonia was the predominant manifestation, occurring in seven patients, and eight patients presented with bacteremic disease. Diabetes mellitus was the most common underlying condition (7/9), followed by chronic liver disease and previous tuberculosis. Most patients were admitted with sepsis, including four cases complicated by septic shock. Two patients developed rapidly progressive pulmonary melioidosis with acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) and died despite intensive antimicrobial and supportive therapy, including one previously healthy individual. The remaining seven patients survived. TTS1 qPCR confirmed all available isolates, while recA sequencing demonstrated the presence of at least two closely related sequence variants among circulating isolates. Antimicrobial susceptibility testing by broth microdilution showed preserved susceptibility to amoxicillin/clavulanic acid, ceftazidime, imipenem, and trimethoprim/sulfamethoxazole in all tested isolates. This report represents, to our knowledge, the first published clinical case series of melioidosis from Phu Quoc Island. The findings highlight the broad clinical spectrum of melioidosis and its potential for rapid progression to life-threatening pneumonia, septic shock, and multiorgan failure. Clinicians should maintain a high index of suspicion in patients presenting with severe pneumonia or sepsis, particularly during the rainy season and among individuals with diabetes mellitus or chronic liver disease. Strengthening conventional microbiological capacity, including timely blood culture, accurate organism identification, and standardized antimicrobial susceptibility testing, remains essential for improving diagnosis and patient outcomes in geographically isolated settings.

PMID 43009814
Read full article →
PubMedRespirology case reports2026-11-10

Endobronchial Pulmonary Actinomycosis With Concomitant Tuberculosis Resembling Lung Malignancy on Presentation: A Case Report.

Bogati Safal S, Pradhan Bishal B, Thapa Suraksha S, Sijapati Milesh Jung MJ et al.

Pulmonary actinomycosis is a rare, indolent infection accounting for roughly 15% of actinomycosis cases, frequently misdiagnosed as tuberculosis or malignancy owing to nonspecific clinical and radiological features. We report a 68-year-old male smoker with chronic alcohol use who presented with acute-on-chronic dyspnea, cough, and fever. Imaging revealed cavitary lesions, consolidation, ground-glass opacities, and mediastinal lymphadenopathy suggestive of tuberculosis or malignancy. Sputum and initial microbiological workup for tuberculosis were largely negative, though a low-level bronchoalveolar lavage GeneXpert signal prompted empirical anti-tubercular therapy. Bronchoscopy revealed an endobronchial mass, and biopsy demonstrated pathognomonic sulfur granules composed of PAS-positive filamentous organisms, confirming actinomycosis with no malignant cells. The patient was treated with amoxicillin-clavulanate alongside continued anti-tubercular therapy, with symptomatic improvement. This case highlights actinomycosis as a condition requiring a high index of suspicion when mimicking tuberculosis and lung cancer, reinforcing the necessity of histopathological confirmation for accurate diagnosis and guiding prolonged, appropriate antimicrobial management.

PMID 43006123
Read full article →
PubMedRSC advances2026-11-10

Phytomechanochemical engineering of Bi/MgO interfaces for enhanced solar hydrogen production and multicomponent antibiotic degradation.

Ullah Ihsan I, Kiran Muqaddas M, Nazir Minhas M, Alsabban Merfat M et al.

The development of multifunctional photocatalysts that produce renewable hydrogen (H2) while removing persistent pharmaceutical pollutants offers a promising solution for sustainable energy and water remediation. Herein, we report the first green phytomechanochemical strategy for synthesizing Bi-loaded MgO (Bi x @MgO; x = 0.2, 0.5, or 0.7 wt% MgO) photocatalysts using clove (Syzygium aromaticum) extract as a natural reducing/stabilizing agent combined with solvent-free mechanochemical engineering. Unlike traditional chemical methods for preparing Bi-modified MgO, the current method combines phytochemical processes of Bi3+ reduction and a mechanochemical process for dispersing Bi onto MgO, forming the Bi/MgO interface without post-synthesis annealing. Bi addition leads to modification of both optical and electronic properties of MgO with a simultaneous increase of defect-mediated charge transfer. Bi0.7@MgO showed a decreased band gap of 2.78 eV and more efficient charge separation than that of pure MgO. Under optimal conditions Bi0.7@MgO exhibited a hydrogen production rate of 33.44 mmol g-1 h-1 when illuminated with solar light. The same photocatalyst also removed 98-99% of amoxicillin, cefixime, azithromycin, and ciprofloxacin under simulated solar light irradiation while maintaining high recyclability over six consecutive cycles.

PMID 43005778
Read full article →
PubMedInfection2026-11-10

Prophylactic Post-lung Transplant Bacteriophage Therapy Against XDR Pseudomonas aeruginosa in Cystic Fibrosis: A Case Report.

Milesi Jules J, Baron Sophie Alexandra SA, Eldin Carole C, Mathias Fanny F et al.

Lung transplant recipients (LTRs) with cystic fibrosis (CF) are frequently colonized with multidrug-resistant pathogens, including extensively drug-resistant (XDR) Pseudomonas aeruginosa (PA), which increase peri-transplant morbidity. Bacteriophage therapy (BT) has shown efficacy against XDR bacteria, but its prophylactic use post-transplant has rarely been reported. A 46-year-old woman with CF and chronic lung allograft dysfunction (bronchiolitis obliterans syndrome stage III) after bilateral lung transplantation in 2005 underwent retransplantation in 2024. She was colonized with XDR PA and Aspergillus spp. Peri-transplant prophylaxis included ceftolozane/tazobactam, intravenous and inhaled colistin, amoxicillin/clavulanic acid, and intravenous liposomal amphotericin B. BT was personalized based on phage susceptibility testing (PST) and initiated immediately post-transplant via combined intravenous and endobronchial administration for three weeks. Pulmonary cultures remained negative for XDR PA during this period. The patient ultimately developed multiorgan failure unrelated to XDR PA and died 88 days post-transplant. This is one of the first reported case of prophylactic BT in lung transplantation, achieving pulmonary microbiologic suppression of XDR PA. While the patient's outcome was determined by other complications. Prospective studies are needed to define its efficacy, safety, and optimal administration.

PMID 43007637
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about lansoprazole + amoxicillin + clarithromycin